Please login to the form below
Mimpara
This page shows the latest Mimpara news and features for those working in and with pharma, biotech and healthcare.
NICE set to back Parsabiv for kidney disease complication
be treated with Amgen's older drug Sensipar/Mimpara (cinacalcet) - and provided Amgen supplies the drug at an agreed discount.
Latest news
-
Amgen's chronic kidney disease drug Parsabiv cleared in US
Parsabiv (etelcalcetide) - a follow-up to Amgen's blockbuster Sensipar/Mimpara (cinacalcet) - has been given a green light to treat adult CKD patients on dialysis who develop secondary hyperparathyroidism (sHPT).
-
Amgen wins European approval for Parsabiv
Sensipar/Mimpara blockbuster.
-
FDA knocks back Amgen's chronic kidney disease treatment
up to blockbuster Sensipar/Mimpara.
-
CHMP recommends 19 new medicines for European approval
of Amgen's hyperparathyroidism and parathyroid carcinoma drug Mimpara.
-
Amgen's Sensipar follow-up clears phase III trial
AMG 416 meets objectives in hyperparathyroidism. One of the unsung heroes in Amgen's product portfolio is Sensipar/Mimpara for secondary hyperparathyroidism (HPT), which has grown fairly steadily since its launch
More from news
Approximately 1 fully matching, plus 11 partially matching documents found.
Latest from PMHub
-
PAN and DJM win prestigious Global Award
Creative agency PAN and sister digital agency DJM Solutions have won a prestigious Global Award for their animation of Mimpara Man’ for Amgen. ... Creative agency PAN and sister digital agency DJM Solutions have won a prestigious Global Award for their
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- Lilly’s Olumiant combined with Gilead’s remdesivir hits the mark in COVID-19
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- How COVID-19 is accelerating the threat of antimicrobial resistance
- 20 for 2020 – Five pharma companies to watch
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- Using Artificial Intelligence to Transform Pharma
- Session 4: Systems Innovation Insight and Thinking
- Transforming Unstructured Healthcare Information into Real-World Evidence & Life Saving Insights
- UK COVID-19 vaccine ‘challenge trials’ could intentionally infect participants with virus
- Keytruda doubles five-year survival rate in NSCLC
- EMA fast-tracks review of bluebird bio’s LentiGlobin for sickle cell disease
PMHub
Madmicrobe Studios
MadMicrobe is an award-winning team of animators and science experts creating photo real life-science animation content for the healthcare and...
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
